| Sort alphabetically by company :
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
All
|
 |
|
|
| Date |
Analyst Note |
Full Analyst Report |
| 05-16-13 |
Hikma Raises Outlook on Improved Generic Segment Results |
Hikma Pharmaceuticals PLC |
| 05-14-13 |
Dr. Reddy Completes Fiscal Year Within Our Expectations |
Dr. Reddy Laboratories, Ltd. |
| 05-14-13 |
Dr. Reddy Completes Fiscal Year Within Our Expectations |
Dr. Reddy Laboratories, Ltd. |
| 05-14-13 |
Dr. Reddy Completes Fiscal Year Within Our Expectations |
Dr. Reddy Laboratories, Ltd. |
| 05-14-13 |
Merck KGaA Reports In Line 1Q, Rebif Continues to Benefit from Price Increases |
Merck KGaA |
| 05-14-13 |
Merck KGaA Reports In Line 1Q, Rebif Continues to Benefit from Price Increases |
Merck KGaA |
| 05-13-13 |
New Product Launches Remain Strong as Lundbeck Posts In-Line First Quarter |
H.Lundbeck A/S |
| 05-10-13 |
Actavis Confirms a Potential Deal With Warner |
Actavis Inc |
| 05-10-13 |
Warner Chilcott Earnings Benefit From Cost Reductions, but Long-Term Challenges Remain |
Warner Chilcott PLC |
| 05-09-13 |
Paladin 1Q Results Meet Expectations, On Pace to Beat Full-Year Forecast |
Paladin Labs, Inc. |
| 05-07-13 |
Strong Generic Performance Offsets Weak Branded Sales in Endo's In-Line 1Q |
Endo Health Solutions Inc |
| 05-07-13 |
Seasonal Factors, New Products, and Acquisitions Sustain Perrigo's High Growth |
Perrigo Company |
| 05-03-13 |
Mylans European and Branded Drug Segments Offset Pressure in U.S. Generics Unit |
Mylan Inc |
| 05-02-13 |
Actavis' Generic Pipeline Acumen Supports Strong Near-Term Fundamentals |
Actavis Inc |
| 05-02-13 |
Teva Faces U.S. Generic Pressure, But European, OTC, and Branded Drug Segments Hold Steady |
Teva Pharmaceutical Industries Ltd |
| 05-02-13 |
Valeant Reports In Line 1Q, Again Exceeds Synergy Targets |
Valeant Pharmaceuticals International Inc |
| 05-02-13 |
Valeant Reports In Line 1Q, Again Exceeds Synergy Targets |
Valeant Pharmaceuticals International Inc |
| 05-01-13 |
Pipeline Concerns Cast Doubt on Allergan's Future Growth Potential |
Allergan, Inc. |
| 05-01-13 |
Hospira's Restructuring Costs Continue on Struggling Device Segment |
Hospira, Inc. |
| 04-30-13 |
Competition in Generic Lovenox Market Remains Headwind for Momenta in 2013 |
Momenta Pharmaceuticals, Inc. |
| 04-29-13 |
Rumors Suggest Surprising Possibility of Valeant and Actavis Combination |
Actavis Inc |
| 04-29-13 |
Rumors Suggest Surprising Possibility of Valeant and Actavis Combination |
Valeant Pharmaceuticals International Inc |
| 04-29-13 |
Rumors Suggest Surprising Possibility of Valeant and Actavis Combination |
Valeant Pharmaceuticals International Inc |
| 04-23-13 |
Forest Reports In-Line Fourth-Quarter Results, Releases 2014 Guidance That We Expect it to Beat |
Forest Laboratories, Inc. |
